- Home
- SSSS vs IPSC Comparison
SSSS vs IPSC Comparison
Compare SSSS & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSSS
- IPSC
- Stock Information
- Founded
- SSSS 2010
- IPSC 2019
- Country
- SSSS United States
- IPSC United States
- Employees
- SSSS N/A
- IPSC N/A
- Industry
- SSSS Finance: Consumer Services
- IPSC Medicinal Chemicals and Botanical Products
- Sector
- SSSS Finance
- IPSC Health Care
- Exchange
- SSSS Nasdaq
- IPSC Nasdaq
- Market Cap
- SSSS 143.5M
- IPSC 146.2M
- IPO Year
- SSSS N/A
- IPSC 2021
- Fundamental
- Price
- SSSS $5.83
- IPSC $1.10
- Analyst Decision
- SSSS Buy
- IPSC Strong Buy
- Analyst Count
- SSSS 2
- IPSC 4
- Target Price
- SSSS $6.00
- IPSC $13.00
- AVG Volume (30 Days)
- SSSS 245.8K
- IPSC 864.2K
- Earning Date
- SSSS 11-07-2024
- IPSC 11-05-2024
- Dividend Yield
- SSSS N/A
- IPSC N/A
- EPS Growth
- SSSS N/A
- IPSC N/A
- EPS
- SSSS N/A
- IPSC N/A
- Revenue
- SSSS $5,903,895.00
- IPSC $2,684,000.00
- Revenue This Year
- SSSS N/A
- IPSC $230.56
- Revenue Next Year
- SSSS $6.05
- IPSC $31.85
- P/E Ratio
- SSSS N/A
- IPSC N/A
- Revenue Growth
- SSSS 5.43
- IPSC 7.88
- 52 Week Low
- SSSS $3.32
- IPSC $0.98
- 52 Week High
- SSSS $6.65
- IPSC $5.51
- Technical
- Relative Strength Index (RSI)
- SSSS 55.63
- IPSC 36.74
- Support Level
- SSSS $5.51
- IPSC $0.98
- Resistance Level
- SSSS $6.65
- IPSC $1.74
- Average True Range (ATR)
- SSSS 0.39
- IPSC 0.14
- MACD
- SSSS -0.06
- IPSC -0.04
- Stochastic Oscillator
- SSSS 39.71
- IPSC 15.79
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.
About IPSC Century Therapeutics Inc.
Century Therapeutics Inc is a biotechnology company specializes in leveraging adult stem cells to develop advanced cell therapy products targeting cancer, autoimmune, and inflammatory diseases. Their innovative approach involves a genetically engineered allogeneic cell therapy platform comprising induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and cutting-edge manufacturing capabilities. This comprehensive platform aims to overcome the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and minimizing development and supply risks.